Stocktoria
BIOMARIN PHARMACEUTICAL INC BMRN
BIOMARIN PHARMACEUTICAL INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B | $1.9B | $1.7B | $1.5B | $1.3B | $1.1B |
| R&D expense | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M | $628.1M | $715.0M | $696.3M | $610.8M | $661.9M |
| SG&A expense | $1.2B | $1.0B | $892.4M | $823.2M | $759.4M | $737.7M | $680.9M | $604.4M | $554.3M | $476.6M |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | -$82.3M | -$43.4M | -$100.5M | -$123.5M | -$14.7M | -$803.4M |
| Interest expense | — | — | $17.3M | $16.0M | $15.3M | $29.3M | $23.5M | $43.7M | $42.7M | $39.5M |
| Income tax | $133.6M | $114.9M | $20.9M | $8.0M | -$11.3M | -$903.0M | -$71.0M | -$65.5M | $81.2M | -$200.8M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M | $854.0M | -$23.8M | -$77.2M | -$117.0M | -$630.2M |
| EPS (diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 |
| Operating cash flow | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M | $85.4M | $48.3M | $20.2M | -$8.8M | -$227.8M |
| Free cash flow | $725.0M | $487.4M | $62.6M | $54.9M | $209.0M | -$28.9M | -$96.8M | -$124.4M | -$208.0M | -$376.2M |
| Cash & equivalents | $1.3B | $942.8M | $755.1M | $724.5M | $587.3M | $649.2M | $437.4M | $494.0M | $598.0M | $408.3M |
| Inventory | $1.3B | $1.2B | $1.1B | $894.1M | $776.7M | $698.5M | $680.3M | $530.9M | $475.8M | $355.1M |
| Total assets | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B | $5.8B | $4.7B | $4.4B | $4.6B | $4.0B |
| Total liabilities | $1.5B | $1.3B | $1.9B | $1.8B | $1.7B | $1.7B | $1.6B | $1.5B | $1.8B | $1.3B |
| Shareholders' equity | $6.1B | $5.7B | $5.0B | $4.6B | $4.3B | $4.1B | $3.1B | $3.0B | $2.8B | $2.8B |
Growth · year-over-year · Revenue CAGR 12.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +12.9% | +18.0% | +15.4% | +13.5% | -0.8% | +9.2% | +14.3% | +13.5% | +17.6% | +25.5% |
| Net income growth | -18.3% | +154.6% | +18.4% | — | -107.5% | — | — | — | — | — |
| EPS growth | -18.6% | +154.0% | +16.0% | — | -107.8% | — | — | — | — | — |
| Free cash flow growth | +48.7% | +679.0% | +13.9% | -73.7% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.